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Aims: Some studies suggested that abnormal diastolic dysfunction was an
early manifestation of Hypertrophic Cardiomyopathy (HCM) and that Tissue
Doppler Imaging (TDI) was able to correctly identify mutation carriers before
the development of hypertrophy. Data are however limited and still controver-
sial. We therefore performed a systematic analysis of Echocardiography, TDI
and ECG in familial HCM to identify predictive parameters for genetic status.
Methods and Results: We recruited 120 adults spread out in three groups:
HCM patients with hypertrophy (LVH+, n=48), mutation carriers without
hypertrophy (LVH-/G+, n=24), normal control subjects (n=48). Several
parameters were significantly different in G+/LVH- as compared to controls,
including septal Ea peak velocity. Multivariate logistic regression identified
three Echographic/TDI independent predictors for genetic status in LVH-free
subjects: the inter-ventricular/left posterior wall (IVS/LPW) ratio, the relative
wall thickness (RWT) and the septal E/Ea ratio. An Echo/TDI score deter-
mined after ROC analysis, showed 67% sensitivity and 96% specificity for the
identification of mutation carriers. In comparison, sensitivity and specificity of
septal Ea peak velocity (<13 cm/s) were 63% and 69% respectively. Major
ECG abnormalities were not correlated with the Echo/TDI score and sensi-
tivity of ECG was only 33%.
Conclusion: Although DTI velocities alone were not reliable enough to
identify LVH-free mutation carriers in HCM, a new Echo/TDI score can
achieve preclinical diagnosis with high accuracy. Abnormal LV remodeling,
and not only functional abnormalities, might be an early manifestation of
HCM in human. 
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Objectives: ECMO is an effective technique to provide emergency
mechanical circulatory assistance for patients with cardiogenic shock refrac-
tory to conventional medical therapies. For patients outside our institution we
create a Heliported Remote Cardiac Assist unit to implant the ECMO. Our
study was undertaken to evaluate the feasibility of the procedure and the
results of our experience.
Methods: Between March 2006 and June 2008 38 consecutive patients in
acute cardiogenic shock were implanted with percutaneous ECMO by our heli-
ported team.
Results: Mean distance from our ICU was 42 miles (1-143). Maximal time
limit between phone call and implantation was 90 min. Mean LVEF evaluated
by TTE was 19 ± 5%. Indications were fulminant myocarditis, pharmacologic
suicide attempt, acute myocardial infarction, post-partum cardiopathy, end-
stage dilated cardiomyopathy. They received a percutaneous veno-arterial fem-
oral ECMO with immediate reperfusion of the limb. Seventeen patients (45%)
were successfully weaned from ECMO after 9.4 ± 8.7 days. Four patients
(11%) were transplanted. One patient (3%) was switched to a left ventricular
assist device and successfully transplanted. Twenty-one patients (55%) sur-
vived to hospital discharge.
Conclusions: The Heliported Cardiac Remote Assist unit allowed the
emergent implant of ECMO support and could rescue 55% of otherwise lethal
cardiogenic shock patients in remote institutions.
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Background: Left ventricular non compaction (LVNC) is a recently iden-
tified cardiomyopathy, characterized by an excessively prominent trabecular
meshwork and deep intertrabecular recesses. Some genes have been described
as responsible for LVNC, including TAZ and LDB3, but the precise preva-
lence of these genes and the impact of mutation screening in clinical practice
are poorly understood.
Objective: To assess the prevalence of mutations in TAZ (tafazzin, Xq28)
and LDB3 (LIM domain-binding3/Cypher/ZASP, 10q23.2) genes in a large
cohort of patients with LVNC, whatever the familial context.
Methods: DNA was extracted from a population of 59 consecutive patients
with a definitive diagnosis of LVNC (Echo core lab), from the French registry
of LVNC. Direct sequencing of exons and intron-exon boundaries was per-
formed with ABI Prism 3100 Genetic Analyzer (Applied Biosystems). The
suspected mutations were tested in a control population (>240 chromosomes);
segregation within the families were analysed when available; evolutive con-
servation among various species were analysed by multiple alignement.
Results: We identified two new missense mutations in the TAZ gene
(Phe128Ser and Met155Val) in two index male patients. No mutation was
observed in the LDB3 gene, but two new genetic polymorphisms. The preva-
lence of TAZ mutations was 3% (2/59) and 0% for LDB3.
Conclusion: Mutations in TAZ gene were not unfrequent in LVNC whereas
no mutation was observed in LDB3 gene. These findings may have impact for
LVNC mutation screening strategy in clinical practice, and also for genetic
counselling as TAZ mutations are associated with X-linked inheritance.
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Background: The recent European Guidelines for the treatment of CHF
2008 underlined that the majority of patient with CHF and COPD can safely
tolerate β-blocker therapy.
Aims: The IMPACT-RECO program III analysed the impact of NYHA
class and of comorbidities on therapeutic management of French outpatients
with stable CHF and left ventricular ejection fraction (LVEF) < 40%.
Methods: This survey was carried out from March 2007 to December 2007
among randomly selected French private cardiologists. 1574 patients with CHF
and LVEF < 40% were included. Key demographics including comorbidities
such as asthma and COPD, as well as ongoing medical treatment of CHF were
collected. Physicians were asked about reasons for not prescribing β-blockers.
Results: Mean age was 71 ± 11 years, 75% of the patients were men, 34%
were in NYHA class III-IV, 54% had coronary artery disease, 30% atrial
fibrillation and the mean LVEF was 34 ± 7%. 78.3% of the patients received
a β-blocker, and asthma or BPCO were reported in 13.7%. 341 patients were
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not receiving β-blockers. The first reason for non-prescription was presumed
contra-indication in 51.9% (177 pts). This contra-indication was asthma or
COPD in 71%, symptomatic hypotension in 15%, bradycardia in 12% and
other problems in 8% . The second reason for non prescribing β-blockers was
previous side effects in 35.2% (120 pts) including heart failure decompensa-
tion in 39%, symptomatic hypotension in 36%, asthenia in 26%, bradycardia
in 18%, impotence in 5% and others in 6%. Lastly, in 10.9% of patients
without β-blockers, the reason for non prescription was fear of potential side
effect.
Conclusion: Respiratory disease remains the main reason for not pre-
scribing β-blockers in CHF despite the fact that selective β-blockers are now
recommended in this population. Room remains for improvement in β-blockers
prescription rate in CHF patients with concomitant COPD, underscoring the
importance of pursuing education of cardiologists.
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Introduction: The multivalvular endocarditis is rare, frequently involving
two valves, and is associated with bad prognosis.
Objective: To compare clinical, microbiological and in hospital prognostic
of multivalvular infective endocarditis with single valve infective endocarditis.
Methods and patients:This is a retrospective study; included 225 patients
admitted between 2001 and 2005 for management of infective endocarditis.
Subsequently, our population was divided into two groups: Group 1: multival-
vular patients (29 patients), Group 2: monovalvular patients (196 patients).
Results: Group1’s patients were younger. Most of patients of two groups
had underlying heart disease, essentially rheumatic heart disease.
In group1, there is more mitral insufficiency, more aortic insufficiency
(p=0.002), but less aortic stenosis. Groups’ 1 patients have more mechanical
valves prosthesis (p=0,004). The germ most frequently involved was the sta-
phylococcus in case of multivalvular disease (46.7% vs 37.3%) and strepto-
coccus in case of monovalvular disease (26.7% vs 38.2%), but without a
significant difference in the both cases. The localization of vegetations in multi
valvular IE were: mitro aortic in 25 cases.
In the TTE, there are more vegetations in group 1 :(p=0,048). Vegetations
with size between 10 and 15 mm are more frequent in the group 1(p=0,019).
Valvular perforations are more frequent (p=0,070). Evolution to valvular
abscess (p=0,414), and acute pericardial effusion (p=0,051) was more frequent
in group 1.
During their hospital period, urgent surgical indication was more frequent
in the group 1(62, 1% vs. 51, 3%; p=0,279), with more frequent hemodynamic
indication (72, 2% vs. 47%; p=0,049). Hospital mortality is higher in the
group 1 (21, 4% vs. 17, 2%; p=0,586), but without a statistical significance.
Conclusion: Mutivalvular endocarditis has specific characteristics: Staphy-
lococcus is the more incriminated germ. It is associated to more complications,
and necessitates more urgent surgery because of acute left heart failure.
084
Additive role of beta blockade in determining positive response to car-
diac resynchronization therapy
Isabella Kardasz, Gabriele Borelli, Paola Bendinelli, Lorenzo Rondinini,
Giulio Zucchelli, Maria Grazia Bongiorni, Rita Mariotti
University of Pisa, Cardiothoracic and Vascular Department, Pisa, Italie
Cardiac resynchronization therapy (CRT) and beta blockers (BB) are
effective in advanced heart failure (HF). Often, due to side effects, BB are
not used or dose not increased. We evaluated the titration of BB therapy
with carvedilol (Carv) in CRT Responders (R) and Not Responders (NR),
recruiting 65 HF outpatients (pts) with CRT indication and on optimal treat-
ment [70% males; age 67.9±12.6 years, ys; NYHA 2.7±0.7; aetiology 44%
coronary artery disease (CAD), 43% dilated cardiomyopathy (DCM)]. All
underwent ECG, echocardiography, NYHA evaluation before and after 1 y
of CRT. Considering NYHA response and improvement of systolic left ven-
tricular function (EF,%), R (ΔNYHA> 1 and/or ΔEF> 5%) and NR were
defined. During follow-up, Carv was titrated. Basally R and NR were sim-
ilar for age, sex, HF aetiology (R 40% CAD, 42.5% DCM; NR 48% CAD,
40% DCM), QRS duration (168±32 vs 178±29 msec), end-diastolic (EDV,
ml), end-systolic (ESV) volume, EF (R 25.1±7.9 NR 27.4±8.2), BB treat-
ment (85 vs 88%) and Carv dose (16.3±18.6 vs 13.2±10.3 mg/day). Only
basal NYHA (R 2.9±0.7 NR 2.4±0.6, p=0.002) was significantly different.
There was no significant difference in QRS duration postCRT (R 123±32,
NR 127±36 msec). After 1 y, R showed greater variation of EDV and ESV
(ΔEDV -45±46 vs -2±56 p=0.01; ΔESV -46±46 vs -1±45 p=0.003) and
mitral regurgitation entity (-0.5±0.7 vs 0±0.7 p=0.02). After 1 y there was
an overall increase of pts on BB (92.5 vs 92%), but R achieved a greater
Carv dose (25.1±20.4 vs 14.5±7.3 mg/day p=0.002, Δdose 8.7±11 vs
1.2±10.7 p=0.009). Carv dose increase and EF improvement were correlated
(r=0.40, p=0.02), while dose increase and ventricular remodeling (LVR)
were negatively related (ΔEDV r=0.42 p=0.02; ΔESV r=0.45 p=0.01). In
both groups CRT allows to introduce and augment BB dose, but only in R
dose increase is statistically significant, correlating with LVR regression.
Such results suggest an addictive role of BB titration in determining CRT
positive response.
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Rationale: HF treatment is often started during hospitalisation. It
appeared interesting to describe the evolution of treatment after hospital
discharge.
Objectives: To describe changes in HF treatment since hospital discharge
after stratification on the time elapsed between discharge and beginning of the
survey.
Methods: Cross sectional observational survey with retrospective collec-
tion of data at hospital discharge. Patients must have been diagnosed with HF
and have been hospitalised for HF within the previous 18 months.
Results: 1452 HF patients met the inclusion criteria and started the survey.
1170 (67% males, age 72±11 years, LVEF 40%±13%) have had at least one
visit by the cardiologist between hospital discharge and entry in the survey.
Patients were stratified according to the time since hospital discharge (<3
months N=414, 3-6 months N=297, 6-12 months N=296, 12 to 18 months
N=163). At hospital discharge, recommended betablocker, ACEI (of which
perindopril) or ARB, are prescribed respectively to 826 (70,6%), 807 (69,0%)
and 170 (14,5%) patients. Target doses were reached in 87 (10.5%) patients
with betablocker, 411 (50.9%) patients with ACEI, 7 (4.1%) patients with
ARB and 417 (43.4%) patients with either ACEI or ARB. At start of the
survey, target doses were reached in 176 patients (20.4%) treated with
betablockers, 470 patients (59.6%) treated with ACEI, 16 patients (7.2%)
receiving ARB and 484 patients (49.7%) receiving either ACEI or ARB. Rates
of patients reaching the target dose for betablockers increased significantly
with time (from 19.5% to 29.8% p=0.01). No significant changes were noticed
for ACEI or ARB.
Conclusion: Treatment strategies for Heart Failure started at hospital are
well followed and amplified by French outhospital cardiologists after hospital
discharge.
